Bruker (NASDAQ:BRKR) Stock Rating Upgraded by The Goldman Sachs Group

by · The Markets Daily

Bruker (NASDAQ:BRKR – Get Free Report) was upgraded by equities researchers at The Goldman Sachs Group from a “strong sell” rating to a “strong-buy” rating in a research note issued to investors on Monday, Zacks reports.

Several other research analysts have also recently weighed in on the stock. Leerink Partners boosted their price target on shares of Bruker from $60.00 to $70.00 and gave the company an “outperform” rating in a research report on Tuesday, July 7th. Stifel Nicolaus set a $50.00 target price on shares of Bruker in a research note on Wednesday, August 5th. Barclays increased their price target on shares of Bruker from $53.00 to $60.00 and gave the company an “overweight” rating in a research note on Wednesday, June 24th. Citigroup reduced their price target on shares of Bruker from $60.00 to $53.00 and set a “hold” rating on the stock in a research report on Wednesday, August 5th. Finally, TD Cowen reaffirmed a “hold” rating on shares of Bruker in a research note on Wednesday, July 15th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $57.00.

View Our Latest Report on BRKR

Bruker Trading Down 2.5%

Shares of BRKR opened at $59.67 on Monday. Bruker has a 52-week low of $30.09 and a 52-week high of $65.30. The stock has a market cap of $9.09 billion, a PE ratio of -85.24, a price-to-earnings-growth ratio of 1.87 and a beta of 1.26. The firm’s fifty day moving average is $58.27 and its two-hundred day moving average is $50.44. The company has a quick ratio of 0.92, a current ratio of 1.85 and a debt-to-equity ratio of 0.76.

Bruker (NASDAQ:BRKR – Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The medical research company reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.11. The firm had revenue of $838.50 million for the quarter, compared to the consensus estimate of $853.57 million. Bruker had a negative net margin of 2.35% and a positive return on equity of 12.47%. The company’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same period last year, the firm posted $0.32 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Research analysts forecast that Bruker will post 2.12 earnings per share for the current fiscal year.

Insider Transactions at Bruker

In other Bruker news, VP Mark Munch sold 2,000 shares of the stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $52.87, for a total transaction of $105,740.00. Following the sale, the vice president directly owned 134,806 shares in the company, valued at $7,127,193.22. This represents a 1.46% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 27.20% of the stock is currently owned by company insiders.

Institutional Trading of Bruker

A number of large investors have recently modified their holdings of the stock. Hsbc Holdings PLC purchased a new stake in Bruker during the 2nd quarter worth about $5,252,000. Edmond DE Rothschild Holding S.A. acquired a new position in shares of Bruker during the second quarter worth about $169,899,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Bruker during the second quarter worth approximately $4,536,000. Legal & General Group Plc acquired a new stake in Bruker in the second quarter valued at approximately $8,742,000. Finally, Tidal Investments LLC lifted its stake in Bruker by 180.4% in the second quarter. Tidal Investments LLC now owns 29,092 shares of the medical research company’s stock worth $1,751,000 after acquiring an additional 18,715 shares during the last quarter. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Bruker Company Profile

(Get Free Report)

Bruker Corporation develops and manufactures scientific instruments, analytical systems and software used to study the chemical, physical and biological properties of materials. Its customers include universities, pharmaceutical and biotechnology companies, industrial manufacturers, hospitals, government laboratories and other research organizations.

The company’s product portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, X-ray analysis instruments, optical and molecular spectroscopy systems, microscopy and nanoanalysis tools, and instruments for microbiology and spatial biology.

Featured Stories